Strategy to Improve Half-Life of DGAT2 Inhibitor Ervogastat: Discovery of PF-07202954

Please copy the URL and add it into your RSS Feed Reader.

Facebook X Linkedin Weibo

Download PDF

Synfacts 2023; 19(12): 1265
DOI: 10.1055/s-0043-1763573

Innovative Drug Discovery and Development

Contributor(s):

Antonia F. Stepan (Roche)

,

Seong Heon Kim (Hyundai Pharm)

DGAT2 inhibitor - PF-07202954 - Ervogastat - half-life - NASH - clinical candidate

Article published online:
15 November 2023

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany